Matches in SemOpenAlex for { <https://semopenalex.org/work/W2088897722> ?p ?o ?g. }
- W2088897722 endingPage "717" @default.
- W2088897722 startingPage "704" @default.
- W2088897722 abstract "In this study, we investigated the effects of low-dose antithymocyte globulin (ATG, thymoglobulin) in the prevention of acute graft-versus-host disease (aGVHD) in mismatched, unrelated hematopoietic stem cell transplantations (uHSCTs) in patients with the single disease entity of acute myelogenous leukemia (AML). Patients (n = 103) with a variable risk for AML who received uHSCTs from available Asian and Caucasian donors were enrolled. First, we compared HLA-matched (group 1, n = 54) and HLA-mismatched (group 2, n = 49) transplantation patients. Then, we divided the patients in group 2, who had received transplants from allele(s)/antigen-mismatched donors, into 2 subgroups: patients who used ATG (group 3, n = 24) and those who did not (group 4, n = 25). To prevent the development of aGVHD, the patients in group 3 received ATG at a dose of 1.25 mg/kg body weight per day for 2 consecutive days, together with our standard regimen of methotrexate (MTX) and tacrolimus. The median CD34(+) cell infusion was 4.2 x 10(6)/kg (range: 1.2-34.4). The median patient age was 41 years (range: 16-57), and the median follow-up duration of patients who were event-free survivors was 23 months (range: 2-72). The overall incidences of aGVHD and chronic GVHD (cGVHD) were 38% and 56%, respectively. Of 48 evaluable patients in group 2, 10 (21%) developed moderate to severe aGVHD (grades II-IV). In contrast, 2 (8%) of the 24 patients in group 3 and 7 (29%) of the 24 evaluated patients in group 4 required therapy for aGVHD (grades II-IV; P = .038). The incidence of cGVHD was not different between groups 3 and 4. The estimated probabilities of overall survival (OS) and event-free survival (EFS) at 2 years for group 2 were 55% and 44%, respectively. In comparison, the estimated probabilities of OS and EFS at 2 years for groups 3 and 4 were 68% versus 38% (P = .043) and 58% versus 38% (P = .103), respectively. The overall cumulative incidence of nonrelapse mortality (NRM) was 29% in group 2. The cumulative incidence of NRM differed markedly between group 3 (16%; 95% confidence interval [CI], 4%-28%) and group 4 (44%, 95% CI, 34%-54%) (P = .013). We found no difference in cytomegalovirus (CMV) reactivation between groups 3 and 4. These results suggest that in mismatched uHSCT, a low dose of ATG (total 2.5 mg/kg) may prevent moderate to severe aGVHD, with comparable rates of relapse and CMV reactivation and a greatly decreased rate of NRM." @default.
- W2088897722 created "2016-06-24" @default.
- W2088897722 creator A5009032518 @default.
- W2088897722 creator A5013483628 @default.
- W2088897722 creator A5036020306 @default.
- W2088897722 creator A5044372572 @default.
- W2088897722 creator A5050292329 @default.
- W2088897722 creator A5055206475 @default.
- W2088897722 creator A5057482418 @default.
- W2088897722 creator A5059291757 @default.
- W2088897722 creator A5061707434 @default.
- W2088897722 creator A5086415059 @default.
- W2088897722 creator A5086500437 @default.
- W2088897722 date "2009-06-01" @default.
- W2088897722 modified "2023-10-13" @default.
- W2088897722 title "Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia" @default.
- W2088897722 cites W107716097 @default.
- W2088897722 cites W1492609361 @default.
- W2088897722 cites W1519981272 @default.
- W2088897722 cites W1981207715 @default.
- W2088897722 cites W1984655249 @default.
- W2088897722 cites W1989930968 @default.
- W2088897722 cites W1990773093 @default.
- W2088897722 cites W2016198582 @default.
- W2088897722 cites W2016231795 @default.
- W2088897722 cites W2022458498 @default.
- W2088897722 cites W2061119990 @default.
- W2088897722 cites W2073236922 @default.
- W2088897722 cites W2114144492 @default.
- W2088897722 cites W2127419842 @default.
- W2088897722 cites W2167805334 @default.
- W2088897722 cites W2320331489 @default.
- W2088897722 cites W2331861739 @default.
- W2088897722 cites W2409904921 @default.
- W2088897722 cites W58931608 @default.
- W2088897722 doi "https://doi.org/10.1016/j.bbmt.2009.02.010" @default.
- W2088897722 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19450755" @default.
- W2088897722 hasPublicationYear "2009" @default.
- W2088897722 type Work @default.
- W2088897722 sameAs 2088897722 @default.
- W2088897722 citedByCount "70" @default.
- W2088897722 countsByYear W20888977222012 @default.
- W2088897722 countsByYear W20888977222013 @default.
- W2088897722 countsByYear W20888977222014 @default.
- W2088897722 countsByYear W20888977222015 @default.
- W2088897722 countsByYear W20888977222016 @default.
- W2088897722 countsByYear W20888977222017 @default.
- W2088897722 countsByYear W20888977222018 @default.
- W2088897722 countsByYear W20888977222019 @default.
- W2088897722 countsByYear W20888977222020 @default.
- W2088897722 countsByYear W20888977222021 @default.
- W2088897722 countsByYear W20888977222023 @default.
- W2088897722 crossrefType "journal-article" @default.
- W2088897722 hasAuthorship W2088897722A5009032518 @default.
- W2088897722 hasAuthorship W2088897722A5013483628 @default.
- W2088897722 hasAuthorship W2088897722A5036020306 @default.
- W2088897722 hasAuthorship W2088897722A5044372572 @default.
- W2088897722 hasAuthorship W2088897722A5050292329 @default.
- W2088897722 hasAuthorship W2088897722A5055206475 @default.
- W2088897722 hasAuthorship W2088897722A5057482418 @default.
- W2088897722 hasAuthorship W2088897722A5059291757 @default.
- W2088897722 hasAuthorship W2088897722A5061707434 @default.
- W2088897722 hasAuthorship W2088897722A5086415059 @default.
- W2088897722 hasAuthorship W2088897722A5086500437 @default.
- W2088897722 hasBestOaLocation W20888977221 @default.
- W2088897722 hasConcept C126322002 @default.
- W2088897722 hasConcept C203014093 @default.
- W2088897722 hasConcept C2776960273 @default.
- W2088897722 hasConcept C2777408962 @default.
- W2088897722 hasConcept C2777630719 @default.
- W2088897722 hasConcept C2778461978 @default.
- W2088897722 hasConcept C2779972918 @default.
- W2088897722 hasConcept C2781059491 @default.
- W2088897722 hasConcept C2909675724 @default.
- W2088897722 hasConcept C2911091166 @default.
- W2088897722 hasConcept C71924100 @default.
- W2088897722 hasConcept C90924648 @default.
- W2088897722 hasConceptScore W2088897722C126322002 @default.
- W2088897722 hasConceptScore W2088897722C203014093 @default.
- W2088897722 hasConceptScore W2088897722C2776960273 @default.
- W2088897722 hasConceptScore W2088897722C2777408962 @default.
- W2088897722 hasConceptScore W2088897722C2777630719 @default.
- W2088897722 hasConceptScore W2088897722C2778461978 @default.
- W2088897722 hasConceptScore W2088897722C2779972918 @default.
- W2088897722 hasConceptScore W2088897722C2781059491 @default.
- W2088897722 hasConceptScore W2088897722C2909675724 @default.
- W2088897722 hasConceptScore W2088897722C2911091166 @default.
- W2088897722 hasConceptScore W2088897722C71924100 @default.
- W2088897722 hasConceptScore W2088897722C90924648 @default.
- W2088897722 hasIssue "6" @default.
- W2088897722 hasLocation W20888977221 @default.
- W2088897722 hasLocation W20888977222 @default.
- W2088897722 hasOpenAccess W2088897722 @default.
- W2088897722 hasPrimaryLocation W20888977221 @default.
- W2088897722 hasRelatedWork W1967987848 @default.
- W2088897722 hasRelatedWork W1996834922 @default.
- W2088897722 hasRelatedWork W2023201732 @default.
- W2088897722 hasRelatedWork W2052387735 @default.